Latest Conference Articles

A retrospective analysis of the phase 3 IMmotion010 trial suggests that KIM-1 levels might hold promise as a biomarker in renal cell carcinoma.

Lenvatinib in combination with pembrolizumab yielded a greater clinical benefit rate compared with sunitinib in advanced clear cell renal cell carcinoma, regardless of patient biomarker subtype.

Envafolimab given subcutaneously with lenvatinib shows promise in patients with advanced endometrial cancer who were not microsatellite instability-high or mismatch repair deficient after prior lines of therapy.

Data from DREAMM-7 showed comparable patient-reported outcomes between belantamab/bortezomib/dexamethasone and daratumumab/bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

A step-up dosing regimen of teclistamab with prophylactic tocilizumab for relapsed/refractory multiple myeloma showed promising responses in a small patient cohort.

A study found that enfortumab vedotin with pembrolizumab significantly improves survival and maintains quality-of-life compared with chemotherapy for locally advanced or metastatic urothelial cancer.

Treatment with talquetamab demonstrated promising safety and efficacy findings when used in relapsed/refractory multiple myeloma, including patients with comorbidities and poor functional status.

PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.

Retreatment with daratumumab showed response rates similar to overall response rates from initial daratumumab-based regimens in a retrospective study.

Rebecca Shatsky, MD, discusses findings from the ISPY2.2 trial presented at the 2024 ASCO Annual Meeting.

In a phase 3 trial, BVd demonstrated a substantial improvement in progression-free survival compared with DVd for patients with relapsed/refractory multiple myeloma.

Based on a post-hoc analysis of the ARAMIS trial, darolutamide was associated with lower rates of PSA and radiological progression vs placebo as well as improving overall survival in patients with nonmetastatic castration-resistant prostate cancer.

With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative tumor infiltrating lymphocytes did not serve as a biomarker of improved clinical outcomes of nivolumab plus ipilimumab in metastatic ccRCC.

The addition of liver transplantation to chemotherapy led to improved overall survival at 5 years in patients with definitively unresectable colorectal cancer metastasis in the liver.

Trastuzumab deruxtecan therapy led to superior PFS vs chemotherapy in pretreated, HR-positive, HER2-low metastatic breast cancer as well as ‘ultralow’ disease with IHC 0 and membrane staining.

Patients with ROS1-positive non–small cell lung cancer responded to the next-generation inhibitor taletrectinib with acceptable toxicity.

Results from the ASTREON trial showed a similar safety profile of oral azacitidine at a dose of 200-mg and 300-mg in patients with lower- to intermediate-risk MDS.

Retrospective data from the International Metastatic Renal Cell Carcinoma Database Consortium showed limited response rates in patients treated with tyrosine kinase inhibitors who received prior lenvatinib.

Neoadjuvant enfortumab vedotin displayed promising outcomes for cisplatin-ineligible MIBC patients, achieving a 2-year EFS rate of 62.0%. Safety was affirmed with no treatment-related delays in surgery.

A retrospective study revealed outcomes of sequencing the 2 antibody-drug conjugates trastuzumab deruxtecan and sacituzumab govitecan in patients with metastatic breast cancer.

A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from direct sequencing the two agents.

Darolutamide delays time to progression from mHSPC to mCRPC vs placebo while also increasing overall survival benefit.

Zanidatamab therapy led to confirmed responses, disease control, and favorable overall survival in pretreated HER2+ biliary tract cancer in an update of the HERIZON-BTC-01 trial.

Adding atezolizumab to bevacizumab plus chemotherapy did not derive benefit in recurrent ovarian cancer.

A post-hoc analysis showed suspending enzalutamide does not impact quality of life in patients with nonmetastatic hormone-sensitive prostate cancer in the phase 3 EMBARK trial.

Nivolumab plus ipilimumab demonstrates increased survival and response in patients with ovarian or gynecologic clear cell carcinoma.

By dramatically reducing the risk of disease progression in patients with stage III melanoma neoadjuvant nivolumab plus ipilimumab emerges as a new standard of care in this setting.

Belantamab mafodotin in combination with other therapies shows promise for patients with multiple myeloma following the first relapse.

Recent data shows that telehealth is comparable to quality of life to in-person visits for patients with advanced non–small cell lung cancer.